Doug Mager

987 total citations
10 papers, 864 citations indexed

About

Doug Mager is a scholar working on Epidemiology, Psychiatry and Mental health and Cognitive Neuroscience. According to data from OpenAlex, Doug Mager has authored 10 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 5 papers in Psychiatry and Mental health and 3 papers in Cognitive Neuroscience. Recurrent topics in Doug Mager's work include Substance Abuse Treatment and Outcomes (5 papers), Schizophrenia research and treatment (4 papers) and Inflammatory mediators and NSAID effects (2 papers). Doug Mager is often cited by papers focused on Substance Abuse Treatment and Outcomes (5 papers), Schizophrenia research and treatment (4 papers) and Inflammatory mediators and NSAID effects (2 papers). Doug Mager collaborates with scholars based in United States, India and Australia. Doug Mager's co-authors include Bridget F. Grant, Deborah S. Hasin, Somnath Chatterji, R Vraşti, Wilson M. Compton, Linda B. Cottler, Brenda R. Motheral, Emily R. Cox, John B. Saunders and Rochelle Henderson and has published in prestigious journals such as PEDIATRICS, Drug and Alcohol Dependence and American Journal on Addictions.

In The Last Decade

Doug Mager

10 papers receiving 842 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Doug Mager United States 9 457 326 242 166 159 10 864
Collins E. Lewis United States 18 421 0.9× 424 1.3× 182 0.8× 151 0.9× 108 0.7× 27 936
Robert B. Millman United States 17 571 1.2× 328 1.0× 215 0.9× 218 1.3× 53 0.3× 40 1.1k
Chad D. Emrick United States 15 910 2.0× 415 1.3× 170 0.7× 413 2.5× 208 1.3× 25 1.3k
Michele Morales United States 8 526 1.2× 261 0.8× 109 0.5× 176 1.1× 86 0.5× 11 1.0k
Jon Randolph Haber United States 20 395 0.9× 297 0.9× 55 0.2× 188 1.1× 122 0.8× 37 973
Denis Murphy United Kingdom 8 250 0.5× 269 0.8× 230 1.0× 161 1.0× 134 0.8× 18 956
Hamid Ghodse United Kingdom 18 298 0.7× 287 0.9× 94 0.4× 138 0.8× 58 0.4× 69 909
A T McLellan United States 10 708 1.5× 140 0.4× 150 0.6× 185 1.1× 70 0.4× 14 1.0k
Christina Aivadyan United States 10 373 0.8× 275 0.8× 60 0.2× 188 1.1× 88 0.6× 14 729
Raymond M. Costello United States 16 320 0.7× 243 0.7× 119 0.5× 181 1.1× 67 0.4× 60 793

Countries citing papers authored by Doug Mager

Since Specialization
Citations

This map shows the geographic impact of Doug Mager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doug Mager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doug Mager more than expected).

Fields of papers citing papers by Doug Mager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doug Mager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doug Mager. The network helps show where Doug Mager may publish in the future.

Co-authorship network of co-authors of Doug Mager

This figure shows the co-authorship network connecting the top 25 collaborators of Doug Mager. A scholar is included among the top collaborators of Doug Mager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doug Mager. Doug Mager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Cox, Emily R., et al.. (2003). Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy.. PubMed. 9(11). 735–42. 13 indexed citations
2.
Cox, Emily R., Brenda R. Motheral, Rochelle Henderson, & Doug Mager. (2003). Geographic Variation in the Prevalence of Stimulant Medication Use Among Children 5 to 14 Years Old: Results From a Commercially Insured US Sample. PEDIATRICS. 111(2). 237–243. 144 indexed citations
3.
Cox, Emily R., Brenda R. Motheral, & Doug Mager. (2003). Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).. PubMed. 9(12). 785–94. 7 indexed citations
5.
Cottler, Linda B., Bridget F. Grant, Jack Blaine, et al.. (1997). Concordance of DSM-IV alcohol and drug use disorder criteria and diagnoses as measured by AUDADIS-ADR, CIDI and SCAN. Drug and Alcohol Dependence. 47(3). 195–205. 252 indexed citations
6.
Chatterji, Somnath, John B. Saunders, R Vraşti, et al.. (1997). Reliability of the alcohol and drug modules of the Alcohol Use Disorder and Associated Disabilities Interview Schedule—alcohol/drug-revised (AUDADIS-ADR): an international comparison. Drug and Alcohol Dependence. 47(3). 171–185. 230 indexed citations
7.
Easton, Caroline J., Doug Mager, Berna Uluğ, et al.. (1997). Test-retest reliability of the alcohol and drug use disorder sections of the schedules for clinical assessment in neuropsychiatry (SCAN). Drug and Alcohol Dependence. 47(3). 187–194. 31 indexed citations
8.
Shillington, Audrey M., Linda B. Cottler, Doug Mager, & Wilson M. Compton. (1995). Self-report stability for substance use over 10 years: data from the St. Louis Epidemiologic Catchment Study. Drug and Alcohol Dependence. 40(2). 103–109. 42 indexed citations
9.
Compton, Wilson M., et al.. (1994). Inhalant Use: Characteristics and Predictors. American Journal on Addictions. 3(3). 263–272. 27 indexed citations
10.
Compton, Wilson M., et al.. (1994). Characteristics and Predictors. American Journal on Addictions. 3(3). 263–272. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026